A venture-backed biotech company, developing a clinical stage asset for the treatment of early stage cancer, was populating a dataroom and preparing for negotiations with a major pharmaceutical company. Alacrita was asked to prepare an expert review paper for the lead product which summarized:
- the evidence base for likely efficacy in the primary target market; and
- the potential mechanism(s) of action that underpins such an effect.
The challenge was that the compound, which has had significant clinical exposure, has activity through at least three mainstream anti-cancer pathways, each of which could potentially account for some or all of the observed activity.
Alacrita’s team included a former Big Pharma research director who was able to synthesize the voluminous literature into a unifying mechanistic framework. The report was duly placed into the dataroom where it provided useful support for interactions with the prospective partner’s research team.Back